Antiplatelet Therapy: A Literature Review

365 Words1 Page

Dr. Wheeler:
Per your request, I completed a literature search using UptoDate and GoogleScholar. I performed searches using the terms, drug eluding stents, antiplatelet therapy duration, pci and stents, and antithrombotic therapy. I found some information that may help in answering your question.
In patients with a drug eluding stent dual antiplatelet therapy of aspirin and a P2y12 inhibitor is recommended. The dual antiplatelet therapy will reduce the chances of stenosis, heart attacks and sequentially death. Aspirin and one of the P2y12 inhibitors of which include Clopidogrel, Prasugrel or Ticagrelor has been shown to be most effective. The American College of Chest Physicians Evidence Based Clinical Practice Guidelines recommends that patients who have received percutaneous coronary interventions with drug eluding stents should receive 3 to 6 months of dual antiplatelet therapy. The minimum of 3 months is recommended for limus stents and 6 months is recommended for taxel stents. This recommendation is made with Grade 1A evidence. The shorter duration of dual antiplatelet therapy will reduce the risk of bleeding, however chances of early discontinuation will increase chances of stent thrombosis. …show more content…

In a patient, for example, that may have renal failure, dyslipidemia or diabetes therapy may be warranted longer in order to prevent stent thrombosis. Cutlip recommends that if the patient does not have any major bleeding such as intracranial, retroperitoneal or intraocular that dual antiplatelet therapy can be extended up to 18 months. We must weigh the benefit vs. risks in all patients with drug eluding stents receiving dual antiplatelet

Open Document